Aytu BioPharma, Inc.
General ticker "AYTU" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $24.4M (TTM average)
Aytu BioPharma, Inc. does not follow the US Stock Market performance with the rate: -13.1%.
Estimated limits based on current volatility of 2.6%: low 1.97$, high 2.07$
Factors to consider:
- Total employees count: 83 (-18.6%) as of 2025
- US accounted for 99.9% of revenue in the fiscal year ended 2024-06-30
- Top business risk factors: Operating losses, No profit, Regulatory and compliance, Market competition, Capital requirements
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-06-30 to 2027-06-30
- 2025-06-30 to 2026-06-30 estimated range: [1.19$, 3.01$]
- 2026-06-30 to 2027-06-30 estimated range: [1.00$, 2.59$]
Financial Metrics affecting the AYTU estimates:
- Positive: with PPE of -0.7 at the end of fiscal year the price was neutral
- Positive: -13.52 < Operating profit margin, % of -10.55
- Positive: Industry inventory ratio change (median), % of 0 <= 0.12
- Negative: negative Operating cash flow
- Positive: 12.78 < Shareholder equity ratio, % of 15.27 <= 25.20
- Positive: Inventory ratio change, % of -1.01 <= -0.37
- Positive: -40.59 < Investing cash flow per share per price, % of -19.59
Short-term AYTU quotes
Long-term AYTU plot with estimates
Financial data
| YTD | 2024-06-30 | 2025-06-30 | 2026-06-30 |
|---|---|---|---|
| Operating Revenue | $65.18MM | $66.38MM | $57.57MM |
| Operating Expenses | $66.77MM | $74.21MM | $65.89MM |
| Operating Income | $-1.59MM | $-7.83MM | $-8.31MM |
| Non-Operating Income | $-8.79MM | $-5.92MM | $-5.92MM |
| Interest Expense | $5.06MM | $3.70MM | $1.90MM |
| R&D Expense | $2.77MM | $1.33MM | $0.00MM |
| Income(Loss) | $-10.38MM | $-13.74MM | $-14.23MM |
| Taxes | $2.14MM | $0.44MM | $-0.02MM |
| Other Income(Loss) | $-3.32MM | $0.62MM | $0.00MM |
| Net Income(Loss)* | $-15.84MM | $-13.56MM | $-14.25MM |
| Stockholders Equity | $27.72MM | $18.97MM | $35.27MM |
| Inventory | $12.14MM | $11.43MM | $6.86MM |
| Assets | $118.86MM | $124.18MM | $105.01MM |
| Operating Cash Flow | $-1.39MM | $-1.94MM | $3.28MM |
| Capital expenditure | $0.33MM | $3.23MM | $0.03MM |
| Investing Cash Flow | $-0.33MM | $-2.56MM | $-0.03MM |
| Financing Cash Flow | $-1.26MM | $15.44MM | $-7.90MM |
| Earnings Per Share** | $-2.86 | $-2.16 | $-1.16 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.